FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01
INFORMATION DISCLOSURE	FILING DATE:	March 31, 2004	CONFIRMATION NO.: 5444
STATEMENT BY APPLICANT	APPLICANT:	Tzianabos et al.	
Sheet 20 1 of 7	GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney

d	Æ/		U.S.	PATENT DOCUMENTS			
Exa Capea Initials	Cite No.	U.S. Patent Doc Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY		
		3,849,550		Teitelbaum et al.	11-19-1974		
		4,619,995		Hayes	10-28-1986		
		4,819,617		Goldberg et al.	04-11-1989		
		4,886,787		de Belder et al.	12-12-1989		
		4,937,270		Hamilton et al.	06-26-1990		
		5,126,141		Henry	06-30-1992		
		5,130,417		Stanley et al.	07-14-1992		
		5,140,016		Goldberg et al.	08-18-1992		
		5,158,939		Takayama et al.	10-27-1992		
		5,196,510		Rodwell et al.	03-23-1993		
		5,215,896		Keck et al.	06-01-1993		
		5,331,573		Balaji et al.	07-19-1994		
		5,514,581		Ferrari et al.	05-07-1996		
		5,532,221		Huang et al	07-02-1996		
		5,576,002		Jennings et al.	11-19-1996		
		5,605,938		Roufa et al.	02-25-1997		
		5,679,658		Elson	10-21-1997		
		5,700,906		Arnot et al.	12-23-1997		
		5,705,178		Roufa et al.	01-06-1998		
		5,760,200		Miller et al.	06-02-1998		
		5,888,741		Hendry	03-30-1999		
		6,110,672		Mandel et al.	08-29-2000		
		6,150,459		Mayes et al.	11-21-2000		
		6,294,518		Potter et al.	09-25-2001		
		6,447,765		Horwitz	09-10-2002		
		6,995,237		Zimmerman, Daniel H.	02-07-2006		
		7,163,683		Barstad et al.	01-16-1007		

Examiner's Cite		Foreign Patent Document				e of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	l van	Document	Cited Document MM-DD-YYYY	(Y/N)
EXAMINER:						DATE CONSIDERED:		
		/Nora Ro	oney/					

EXAMINER: Initial if reference considered, whether or noteitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

09/29/2009

Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01	
				FILING DATE:	DATE: March 31, 2004 CONFIRMATION NO.: 5444		
STATEMENT BY APPLICANT			APPLICANT:	Tzianabos et al.			
				00010 40010	1644		
Sheet	2	of	7	GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney	

DE	3704389	Al	Blutspendedienst Dt Rote Kreuz	08-01-1988	Y- Abstract Only
Wo	96/35433	Al	Chitogenics	11-14-1996	
wo	95/31990	Al	Yeda Research and Development Co., Ltd	11-30-1995	
WO	96/07427	Al	The Brigham and Women's Hospital, Inc.	03-14-1996	
wo	96/32119	Al	Yeda Research and Development Co., Ltd.	10-17-1996	
WO	07/092451	A2	The Brigham and Women's Hospital, Inc.	08-16-2007	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, e.c.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
		NCBI Sequence View "Toxin" [Salmonella typhimurium J T2]							
		http://www.ncbi.nim.nih.gov/entrez/viewer.fcgi?db=protein&id=17233414, pages 1-2.							
		No Author Listed, Acute Respiratory Disease Syndrome: What is acute respiratory disease							
		syndrome? American Lung Association 3 pages							
		http://www.lungusa.org/site/apps/nlnet/content3.aspz?c=dvLUK9O0E&b=2058817&content							
		No Author Listed, Lunus study, Meet A Lunus Researcher, www.lunusstudy.org/updates.php.							
		2005;1-2.							
		No Author Listed, Polyethylene Glycols (PEGs). Accessed 3/7/05. 1 page.							
***************************************	1	http://www.mindfully.org/Plastic/Polymers/Polyethylene-Glycols-PEGs.htm							
		No Author Listed, The Werck index . Eleventh Edition 1989:734-735.							
		No Author Listed, VAXA, Systemic lunus erythematosus (SLF), damaging and unpredictable							
		http://www.vaxa.com/arthritis-systemic-lupus-erythematosus.cfm. 1 page.							
		AHARONI et al., Bystander suppression of experimental autoimmune encephalomyelitis by T cell							
		lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998 Nov 2;91(1-							
		2):135-46.							
		AHARONI et al., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin							
		basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10821-6.							
		AHARONI et al., Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. 1997 Jul;58(2):79-87.							
		ARNON et al., New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol. 1996 Apr;243(4 Suppl 1):S8-13. Review.							
		BASU et al., Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem. 1997 Jul-Aug;8(4):481-8.							
		BATTA et al., Conformational stabilization of the altruronic acid residue in the O-specific polysaccharide of Shigella sonnei/Plesiomonas shigelloides. Carbohydr Res. 1997 Dec;305(1):93-9.							
	-	BAZAN et al., Unraveling the structure of IL-2. Science. 1992 Jul 17;257(5068):410-3.							

examiner: /Nora Rooney/	DATE CONSIDERED: 09/29/2009
-------------------------	-----------------------------

^{*} EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO) 1449/A and B (n	nodifie	d PTO/SR/08)	APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE			FILING DATE:	March 31, 2004	CONFIRMATION NO.: 5444	
STATEMENT BY APPLICANT				APPLICANT:	Tzianabos et al.	
. Sheet	3	of	7	GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney

	BOES et al., Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1184-9.	
	COMSTOCK et al., Interstrain variation of the polysaccharide B biosynthesis locus of Bacteroides fragilis: characterization of the region from strain 638R. J Bacteriol. 1999 Oct;181(19):6192-6.	
	COYNE et al., Bacteroides fragilis NCTC9343 produces at least three distinct capsular polysaccharides: cloning, characterization, and reassignment of polysaccharide B and C biosynthesis loci. Infect Immun. 2000 Nov.68(11):6176-81.	
	CRABB et al., T cell regulation of Bacteroides fragilis-induced intraabdominal abscesses. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S178-84. Review.	
	CRAIG, Autologous hematopoietic stem cell transplantation for Crohn's disease. Autoimmun Rev. 2002 Aug; 1(4):244-9. Review.	
	DAHIYAT et al., De novo protein design: fully automated sequence selection. Science. 1997 Oct 3;278(5335):82-7.	
	FRIDKIS-HARELI et al., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol. 1999 Apr 15;162(8):4697-704.	
	FRIDKIS-HARELI et al., Binding of random copolymers of three amino acids to class II MHC molecules. Int Immunol. 1999 May; 11(5):635-41.	
	FRIDKIS-HARELI et al., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cellsspecificity and promiscuity. Proc Natl Acad Sci U S A. 1994 May 24-91(11)4872-6.	+
	FRIDKIS-HARELI et al., Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell Immunol. 1995 Jul;163(2):229-36.	
	GIBSON et al., Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. J Immunol. 1998 May 15;160(10):5000-6.	
	GIBSON et al., The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells. Infect Immun. 1996 Mar;64(3):1065-9.	
	GOLGHER et al., Galactofuranose-containing glycoconjugates of epimastigote and trypomastigote forms of Trypanosoma cruzi. Mol Biochem Parasitol. 1993 Aug;60(2):249-64.	
	HAFLER et al., Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 1;141(1):131-8.	
	HERTL et al., T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006 May;116(5):1159-66. Review.	
	HIRATA et al., Cytokine synthesis of human monocytes stimulated by triple or single helical conformer of an antitumour (1>3)-beta-D-glucan preparation, sonifilan. Zentralbl Bakteriol. 1998 Nov;288(3):403-13.	
	ITOKAZU et al., Abscess formation as a complication caused by postoperative osteomyelitis of the femur. Arch Orthop Trauma Surg. 1998;118(1-2):99-102. Review.	
	JENNINGS et al., Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986 Sep 1;137(5):1708-13.	
AMINER:	DATE CONSIDERED:	

EXAMINER:

/Nora Rooney/

Date considered:
09/29/2009

^{*} EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PT	2 1440/A d P (4 PTO/CD/00)	APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01	
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				FILING DATE:	March 31, 2004	CONFIRMATION NO.: 5444	
STATEMENT BY APPLICANT			APPLICANT:	Tzianabos et al.			
				GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney	
. Sheet	4	of	7	GROOF ART UNIT.	1077	EAAWINER. Hora Madreell Roolley	

	JENNINGS et al., Immunochemistry of group toxoid conjugates. J Immunol. 1981 Sep;127(3)	s A, B, and C meningococcal polysaccharide-tetanus	
		fragilis group in rat intra-abdominal abscesses.	
	Effect of Chain Length of T cell Proliferation. for Microbiol. 1998;98:123. Abstract B-405.	CTC 9343 Capsular Polysaccharide PS A and the Abstracts of the 98 th Gen Mtg of the American Soc	
	KASPER et al., Protective efficacy of immuni infection with Bacteroides fragilis. J Infect Dis	zation with capsular antigen against experimental s. 1979 Nov;140(5):724-31.	
	KASPER et al., Capsular polysaccharides and reference strains: chemical and immunochemic Feb;153(2):991-7.	lipopolysaccharides from two Bacteroides fragilis cal characterization. J Bacteriol. 1983	
	KASPER et al., Surface antigens as virulence Infect Dis. 1979 Mar-Apr;1(2):278-90.	factors in infection with Bacteroides fragilis. Rev	
	KASPER et al., The polysaccharide capsule of immunochemical and morphologic definition.		
	KATO et al., Interleukin 10 reduces mortality Chemother. 1995 Jun;39(6):1336-40.	from severe peritonitis in mice. Antimicrob Agents	
	KNETSCH et al., Polymers with tunable toxic biomaterial surfaces. J Biomed Mater Res A. 2	ity: a reference scale for cytotoxicity testing of 2007 Sep 15;82(4):947-57.	
	KNIREL et al., The structure of O-specific polyseudomonas aeruginosa (a review). Acta Mic	lysaccharides and serological classification of	
	KRAUSE et al., An inhibitor of cell proliferation by N,O-carboxymethyl chitosan. J Invest Surg	ion associated with adhesion formation is suppressed . 1998 Mar-Apr;11(2):105-13.	
	KULICKE et al., Correlation between immuno of different (1>3)-beta-D-glucans. Carbohyd	ological activity, molar mass, and molecular structure r Res. 1997 Jan 2;297(2):135-43.	
	KURUP et al., Antibody response to low-mole allergic bronchopulmonary aspergillosis. J Cli	cular-weight antigens of Aspergillus fumigatus in n Microbiol. 1989 Jun;27(6):1312-6.	
	LINDBERG et al., Virulence factors in infecti characterization of capsular polysaccharide an 1982;35:45-52.	ons with bacteroides fragilis: isolation and d lipopolysaccharide. Scand J Infect Dis Suppl.	
	internal fistulas and intra-abdominal abscesses study. Amer J Gast. 2003;98(7):1545-1555.	tomogrpahy, and ultrasonography in detecting in Chrohn's disease: a prospective comparative	
	components extracted from strains of Bacteroi Immunol Ther Exp (Warsz). 1993;41(2):129-3		
	in a murine model. Fertil Steril. 1994 Jun;61(6		
	MOORE, The List Goes On, New Additions to http://autoimmunedisease.suite101.com/blog.com/	fm/the_list_goes_on. Pages 1-3.	
	MULHOLLAND et al., Strategies for the cont	rol of pneumococcal diseases. Vaccine. 1999 Jul	
XAMINER:	ra Rooney/	DATE CONSIDERED:	

EXAMINER: Initial if reference considered, whether or noteitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01	
				FILING DATE: March 31, 2004		CONFIRMATION NO.: 5444	
				APPLICANT:	Tzianabos et al.		
				GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney	
Sheet	5	of	7	GROOF ART UNIT:	1044	EXAMINER: Nota Madreell Rootley	

	30;17 Suppl 1:S79-84. Review.						
	NIELSEN et al., Applications of peptide nucleic acids. Curr Opin Biotechnol. 1999 Feb;10(1):71-5. Review.						
	OHNO et al., Enhancement of LPS triggered TNF-alpha (tumor necrosis factor-alpha) production by (1>3)-beta-D-glucans in mice. Biol Pharm Bull. 1995 Jan;18(1): 12-633. OHNO et al., Comparison of the immunopharmacological activities of triple and single-helical schizophyllan in mice. Biol Pharm Bull. 1995 Sep;18(9):1242-7.						
	comparison of the pathogenic potential of enc. 1977 Jul;136(1):82-9.	aride of Bacteroides fragilis as a virulence factor: apsulated and unencapsulated strains. J Infect Dis.					
	PANTOSTI et al., Bacteroides fragilis strains Microbiol. 1993 Jul;31(7):1850-5.	express multiple capsular polysaccharides. J Clin					
	9.	toxoid conjugates. J Clin Invest. 1992 Jan;89(1):203-					
	PAVLIAK et al., Structural elucidation of the capsular polysaccharide of Bacteroides fragilis strain 23745M1. Carbohydr Res. 1995 Oct 2;275(2):333-41.						
		PERUMAL et al., Protective effect of interleukin-2 on experimental intra-abdominal abscess development due to Bacteriodes Fragilis. Clinical Research. 1990;38(2):550A.					
	centrations in patients with epilepsy and matched Epilepsy Behav. 2005 Mar;6(2):191-5.						
	REED et al., A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493-497.						
		FELD et al., Biosynthesis of heparin. Assay and properties of the microsomal N-acetyl-D- ninyl N-deacetylase. J Biol Chem. 1980 Feb 10;255(3):922-8.					
	RYPENS et al., Percutaneous drainage of abdominal abscesses in pediatric Crohn's disease. AJR Am J Roentgenol. 2007 Feb:188(2):579-85.						
:	SCHLEGEL et al., A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5061-6. Erratum in: Proc Natl Acad Sci U S A. 1996 May 14;93(10):5061-6. Erratum in: Proc Natl Acad Sci U S A. 1996 May 14;93(10):5061-6.						
	SCHNEIDER et al., De novo design of molecular architectures by evolutionary assembly of drug- derived building blocks. J Comput Aided Mol Des. 2000 Jul;14(5):487-94.						
	SEGAL et al., Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes. 2008 Jun;9(3 Pt 1):250-4.						
	the nicotinic acetylcholine receptor. Biophys J						
	SHAPIRO et al., Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis. J Immunol. 1986 Jul 1;137(1):341-6.						
	SHAPIRO et al., Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med. 1982 Apr 1;155(4):1188-97.						
	SIMMONS et al., Synthesis and membrane permeability of PNA-peptide conjugates. Bioorg Med						
EXAMINER:		DATE CONSIDERED:					
	lora Rooney/	09/29/2009					

* EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.:	10/814,620	ATTY. DOCKET NO.: B0801.70280US01	
			FILING DATE:	March 31, 2004	CONFIRMATION NO.: 5444	
			APPLICANT:	Tzianabos et al.		
Sheet	6	of	7	GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney

	Chem Lett. 1997;7(23):3001-6.							
		s-dependent responses to polysaccharide antigens. J iew.						
	TEITELBAUM et al., Immunomodulation of administration of copolymer 1. Proc Natl Acad	experimental autoimmune encephalomyelitis by oral d Sci U S A. 1999 Mar 30;96(7):3842-7.						
		e T-cell response to myelin basic protein by the						
		TEITELBAUM et al., Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):137-41.						
		TEITELBAUM et al., Unprimed spleen cell populations recognize macrophage-bound antigen with opposite net electric charge. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1693-6.						
		nctional relation to abscess formation. Infect Agents						
	TZIANABOS et al., Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg. 1999 Nov;134(11):1254-9.							
	TZIANABOS et al., IL-2 mediates protection against abscess formation in an experimental model of sepsis. J Immunol. 1999 Jul 15;163(2):893-7.							
	Sepsis 7 Hintanon. 1999 Jul.; 1902(3):939-93. TZIANABOS et al., Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. J Infect Dis. 1998 Jul;178(1):200-6.							
	TZIANABOS et al., Structure and function of							
		nships for polysaccharide-induced intra-abdominal 0-3.						
		tterionic polysaccharides and peptide mimetics stracts of the 99 th General Meeting of the American 30- June 3, 1999, 28 June 1999;99:37-38.						
	TZIANABOS et al., Structural basis for polysi abscess formation. 94th ASM General Meeting 206:65.	accharide-mediated protection against intraabdominal 3. May 23-27, 1994. Las Vegas, Nevada. Abstract B-						
TZIANABOS et al., Characteristics of bacterial polysaccharides that activate T cells. The International Carbohydrate Symposium XVII. July 21, 1994.								
	VIRET et al., Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol Microbiol. 1993 Jan. 7(2):239-52.							
WANG et al., Structure characterization of an abscessogenic capsular polysaccharide from Bacteriodes fragilis by NMR spectroscopy. XIX International Conference of NMR in Biological Systems. Florence, Italy, August 20-25, 2000. Abstract.								
	WEHR et al., Anti-low-density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Alcohol Alcohol. 1997 Jan-Feb;32(1):43-9.							
	WUJEK et al., A carbohydrate polymer that effectively prevents epidural fibrosis at laminectomy sites in the rat. Exp Neurol. 1991 Nov;114(2):237-45.							
EXAMINER:		DATE CONSIDERED:						
/No	ora Rooney/	09/29/2009						

⁸ EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CODA PEC	0-1449/A and B (m	. 4:6-4	DTO/6D/08)	APPLICATION NO.:	10/814,620	31, 2004 CONFIRMATION NO.: 5444
	,		· .	FILING DATE:	March 31, 2004	CONFIRMATION NO.: 5444
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT:	Tzianabos et al.		
Sheet	7	of	7	GROUP ART UNIT:	1644	EXAMINER: Nora Maureen Rooney

YOKOYAMA et al., Adhesion behavior of rat lymphocytes to poly(ether)-poly(amino acid) block and graft copolymers. J Biomed Mater Res. 1986 Sep;20(7):867-78.	
YOSHII, Cytotoxic effects of acrylates and methacrylates: relationships of monomer structures and cytotoxicity. J Biomed Mater Res. 1997 Dec 15;37(4):517-24.	
ZALEZNIK et al., A soluble suppressor T cell factor protects against experimental intraabdominal abscesses. J Clin Invest. 1985 Mar;75(3):1023-7.	
ZHU et al., Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol. 2007 Jan; 122(1):75-84. Epub 2006 Cot 11.	

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filling date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 19.8 and 12870G163. Copies of all other patenticly, publications, jumplished, pending U.S. patent applications or other information listed are provided as required by 37 CFR § 19.8 unless 1) such copies were provided in an IDS in an earlier application that compiles with 37 CFR § 19.8, and 2) the earlier application is relicted upon for an earlier filing date under 35 U.S.C. § 120.]

EXAMINER:	/Nora Rooney/	DATE CONSIDERED: 09/29/2009

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.